
EquitySector - HealthcareVery High Risk
Regular
NAV (27-Aug-26)
Returns (Since Inception)
Fund Size
₹1,371 Cr
Expense Ratio
2.22%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+17.20%
+17.81% (Cat Avg.)
3 Years
+23.89%
+21.74% (Cat Avg.)
5 Years
+15.53%
+15.00% (Cat Avg.)
10 Years
+13.95%
+14.83% (Cat Avg.)
Since Inception
+15.07%
— (Cat Avg.)
| Equity | ₹1,330.9 Cr | 97.08% |
| Others | ₹40.02 Cr | 2.92% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹119.43 Cr | 8.71% |
| Divi's Laboratories Ltd | Equity | ₹76.3 Cr | 5.57% |
| Ajanta Pharma Ltd | Equity | ₹65.84 Cr | 4.80% |
| Caplin Point Laboratories Ltd | Equity | ₹54.11 Cr | 3.95% |
| Lupin Ltd | Equity | ₹49.23 Cr | 3.59% |
| Gland Pharma Ltd | Equity | ₹48.81 Cr | 3.56% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹47.47 Cr | 3.46% |
| Dr Reddy's Laboratories Ltd | Equity | ₹42.48 Cr | 3.10% |
| Alkem Laboratories Ltd | Equity | ₹42.46 Cr | 3.10% |
| Net Current Assets | Cash | ₹39.72 Cr | 2.90% |
| Global Health Ltd | Equity | ₹38.55 Cr | 2.81% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹37.89 Cr | 2.76% |
| Ipca Laboratories Ltd | Equity | ₹36.71 Cr | 2.68% |
| Fortis Healthcare Ltd | Equity | ₹35.44 Cr | 2.58% |
| Anthem Biosciences Ltd | Equity | ₹34.26 Cr | 2.50% |
| Procter & Gamble Health Ltd | Equity | ₹33.02 Cr | 2.41% |
| Rainbow Childrens Medicare Ltd | Equity | ₹32.03 Cr | 2.34% |
| Sai Life Sciences Ltd | Equity | ₹30.2 Cr | 2.20% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹29.94 Cr | 2.18% |
| Cohance Lifesciences Ltd | Equity | ₹29.75 Cr | 2.17% |
| Marksans Pharma Ltd | Equity | ₹29.71 Cr | 2.17% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹28.94 Cr | 2.11% |
| Viyash Scientific Ltd | Equity | ₹27.16 Cr | 1.98% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹26.65 Cr | 1.94% |
| Aurobindo Pharma Ltd | Equity | ₹25.28 Cr | 1.84% |
| Sudeep Pharma Ltd | Equity | ₹23.42 Cr | 1.71% |
| Dr. Lal PathLabs Ltd | Equity | ₹22.9 Cr | 1.67% |
| Metropolis Healthcare Ltd | Equity | ₹22.54 Cr | 1.64% |
| Cipla Ltd | Equity | ₹22.1 Cr | 1.61% |
| Biocon Ltd | Equity | ₹21.2 Cr | 1.55% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹18.29 Cr | 1.33% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹17.79 Cr | 1.30% |
| Pfizer Ltd | Equity | ₹16.56 Cr | 1.21% |
| Windlas Biotech Ltd | Equity | ₹15.99 Cr | 1.17% |
| Alembic Pharmaceuticals Ltd | Equity | ₹15.94 Cr | 1.16% |
| Blue Jet Healthcare Ltd | Equity | ₹15.47 Cr | 1.13% |
| Laxmi Dental Ltd | Equity | ₹14.04 Cr | 1.02% |
| Emcure Pharmaceuticals Ltd | Equity | ₹13.58 Cr | 0.99% |
| Manipal Health Enterprises Limited | Equity | ₹12.54 Cr | 0.91% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹11.14 Cr | 0.81% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹11.05 Cr | 0.81% |
| Aarti Pharmalabs Ltd | Equity | ₹10.01 Cr | 0.73% |
| Orchid Pharma Ltd | Equity | ₹10 Cr | 0.73% |
| Jubilant Pharmova Ltd | Equity | ₹8.39 Cr | 0.61% |
| Syngene International Ltd | Equity | ₹6.3 Cr | 0.46% |
| Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.3 Cr | 0.02% |
Large Cap Stocks
19.35%
Mid Cap Stocks
32.56%
Small Cap Stocks
44.25%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,318.36 Cr | 96.17% |
Standard Deviation
This fund
15.91%
Cat. avg.
16.08%
Lower the better
Sharpe Ratio
This fund
1.01
Cat. avg.
0.90
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.55
Higher the better
Since May 2022
ISIN INF789F01695 | Expense Ratio 2.22% | Exit Load 1.00% | Fund Size ₹1,371 Cr | Age 27 years 2 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹3,62,105 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments